Co-production of AmpC and extended spectrum beta-lactamases in cephalosporin-resistant Acinetobacter baumannii in Egypt

Said, Heba Shehta; Benmahmod, Abdalbagi Basheer; Ibrahim, Ramadan Hassan

doi:10.1007/s11274-018-2571-z

Cited by 15 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the study carried out by Fattouh et al [15], the isolates showed high frequency of resistance to β-lactams/β-lactamase inhibitors, this high resistance is mostly due to βlactamases production [26]. Still high-dose ampicillin/sulbactam monotherapy was effective treatment for critically ill patients with MDR A. baumannii ventilator associated pneumonia [27].…”

Section: Nosupporting

confidence: 80%

See 1 more Smart Citation

Prevalence and antimicrobial resistance pattern of Acinetobacter Baumannii isolates from intensive care units in Zagazig University Hospitals

Salama

Hadhoud

Lotfy

et al. 2021

Microbes and Infectious Diseases

View full text Add to dashboard Cite

Infections with MDR A. baumannii have been reported in various spots of the world including Europe, America, Far East region, the United Arab Emirates, Bahrain, Saudi Arabia, Palestine and Lebanon [4]. It has also been reported in Egypt [5,6]. Such a condition needs continuous monitoring and evaluation to allow better understanding and control. This study aimed to assess A. baumannii as a cause of HAIs in intensive care units (ICUs) of Zagazig University Hospitals and to demonstrate its antimicrobial resistance pattern.

show abstract

Section: Nosupporting

confidence: 80%

“…Trimethoprim/Sulfamethoxazole (TMP-SMX) resistance pattern has been high in most studies, reaching to (92%) [26], even 100% in other studies [23]. These results don't agree with this study which represents half of strains, sensitive to sulfamethoxazole/trimethoprim, this is supported by [28].…”

Section: Nocontrasting

confidence: 51%

Prevalence and antimicrobial resistance pattern of Acinetobacter Baumannii isolates from intensive care units in Zagazig University Hospitals

Salama

Hadhoud

Lotfy

et al. 2021

Microbes and Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…A single colony from overnight growth of E. coli test isolate on LB agar plates was suspended in 100 μl sterile distilled water and heated at 95 °C for 10 min in a heat block. Cell lysates were centrifuged at 10,000 rpm for 5 min, and the supernatants were separated, stored at − 20 °C, and used as templates for polymerase chain reaction (PCR) (Said et al 2018 ).…”

Section: Methodsmentioning

confidence: 99%

Characterization of virulence determinants and phylogenetic background of multiple and extensively drug resistant Escherichia coli isolated from different clinical sources in Egypt

El-baz

Said

Abdelmegeed

et al. 2022

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

Escherichia coli is a multifaceted microbe since some are commensals, normally inhabiting the gut of both humans and animals while others are pathogenic responsible for a wide range of intestinal and extra-intestinal infections. It is one of the leading causes of septicemia, neonatal meningitis, urinary tract infections (UTIs), cystitis, pyelonephritis, and traveler’s diarrhea. The present study aims to survey the distribution and unravel the association of phylotypes, virulence determinants, and antimicrobial resistance of E. coli isolated from different clinical sources in Mansoura hospitals, Egypt. One hundred and fifty E. coli isolates were collected from different clinical sources. Antimicrobial resistance profile, virulence determinants, and virulence encoding genes were detected. Moreover, phylogenetic and molecular typing using ERIC-PCR analysis was performed. Our results have revealed that phylogroup B2 (26.67%) with the greatest content in virulence traits was the most prevalent phylogenetic group. Different virulence profiles and varying incidence of virulence determinants were detected among tested isolates. High rates of resistance to different categories of antimicrobial agents, dramatic increase of MDR (92.67%), and emergence of XDR (4%) were detected. ERIC-PCR analysis revealed great diversity among tested isolates. There was no clustering of isolates according to resistance, virulence patterns, or phylotypes. Our research has demonstrated significant phylogenetic diversity of E. coli isolated from different clinical sources in Mansoura hospitals, Dakahlia governorate, Egypt. E. coli isolates are equipped with various virulence factors which contribute to their pathogenesis in human. The elevated rates of antimicrobial resistance and emergence of MDR and XDR mirror the trend detected globally in recent years. Key points • Clinical E. coli isolates exhibited substantial molecular and phylogenetic diversity. • Elevated rates of antimicrobial resistance and emergence of XDR in pathogenic E. coli. • B2 Phylogroup with the highest VS was the most prevalent among pathogenic E. coli.

show abstract

“…Isolates were recovered from blood (39 samples), sputum (35 samples), urine (16 samples), and wound (10 samples). They were identified as A. baumannii according to standard microbiological techniques, including colony morphology, Gram stain, biochemical reactions, and molecular-based methods (PCR detection of both gltA and bla OXA-51-like genes) (Benmahmod et al 2019 ; Said et al 2018 ).…”

Section: Methodsmentioning

confidence: 99%

A novel pentavalent vaccine candidate completely protects against Acinetobacter baumannii in a mouse model of peritonitis

Hagag

Said

Kenawy

et al. 2022

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

Acinetobacter baumannii is considered as one of the most virulent and infectious organisms that have an increased ability to both evade host immune response and resist various classes of antibiotics, leading to life-threatening infections. Multiple virulence factors have been implicated in the high prevalence rate of A. baumannii in hospitalized and immunocompromised patients. Moreover, improper use of antibiotics has led to the emergence of extensive drug-resistant strains that urgently require alternative strategies to control this superbug. Unfortunately, the availability of a licensed vaccine against A. baumannii infections is still challenged by the vast diversity among A. baumannii strains. Here, we report the development of a novel pentavalent vaccine candidate composed of two recombinant proteins (Wza and YiaD) and a pool of capsular polysaccharides isolated from 3 clinical isolates. We tested this new vaccine in vivo in a mouse model of peritonitis against the standard strain ATCC 19606 in addition to 3 clinical isolates of A. baumannii. Immunization with this vaccine completely protected the challenged mice with 100% survival rate in the case of all the tested bacteria. Further clinical studies are urgently needed to evaluate the efficacy and safety of this proprietary vaccine to protect patients from A. baumannii lethal infections. Key points • Recombinant proteins pool (Wza and YiaD) immunization led to a synergistic immune response. • Capsular polysaccharides pool induced up to 90% protection of tested clinical isolates. • The pentavalent pool showed superiority with 100% survival of immunized mice.

show abstract

Co-production of AmpC and extended spectrum beta-lactamases in cephalosporin-resistant Acinetobacter baumannii in Egypt

Cited by 15 publications

References 38 publications

Prevalence and antimicrobial resistance pattern of Acinetobacter Baumannii isolates from intensive care units in Zagazig University Hospitals

Prevalence and antimicrobial resistance pattern of Acinetobacter Baumannii isolates from intensive care units in Zagazig University Hospitals

Characterization of virulence determinants and phylogenetic background of multiple and extensively drug resistant Escherichia coli isolated from different clinical sources in Egypt

A novel pentavalent vaccine candidate completely protects against Acinetobacter baumannii in a mouse model of peritonitis

Contact Info

Product

Resources

About